Sepia Ink Oligopeptide Induces Apoptosis in Prostate Cancer Cell Lines via Caspase-3 Activation and Elevation of Bax/Bcl-2 Ratio

被引:70
作者
Huang, Fangfang [1 ]
Yang, Zuisu [1 ]
Yu, Di [1 ]
Wang, Jiabin [2 ]
Li, Rong [1 ]
Ding, Guofang [1 ]
机构
[1] Zhejiang Ocean Univ, Sch Food Sci & Pharm, Zhejiang Prov Key Engn Technol Res, Ctr Marine Biomed Prod, Zhoushan 316000, Peoples R China
[2] Zhijiang Hailisheng Grp Co Ltd, Zhoushan 316000, Peoples R China
关键词
oligopeptide; prostate cancer; apoptosis; proliferation; CHEMOTHERAPY; RECEPTOR; FAMILY; ANALOG; DEATH;
D O I
10.3390/md10102153
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Sepia ink oligopeptide (SIO) is a tripeptide extracted from Sepia ink. To test the hypothesis that SIO inhibits prostate cancer by inducing apoptosis, the effects of SIO on the proliferation of three human prostate cancer cell lines were examined using a CCK-8 assay. SIO significantly inhibited the proliferation of DU-145, PC-3 and LNCaP cells in a time-and dose-dependent manner. Flow cytometry studies showed that exposing DU-145, PC-3 and LNCaP cells to 5, 10, or 15 mg/mL SIO for 24 h increased the percentage of the early-stage apoptotic cells from 11.84% to 38.26% (DU-145), 22.76% to 39.96% (PC-3) and 5.05% to 16.11% (LNCaP), respectively. In addition, typical morphologic changes were observed in the cells with acridine orange/ethidium bromide staining. SIO treatment induced strong S and G(2)/M phase cell cycle arrest in a dose-dependent manner in DU-145 and LNCaP. In contrast, SIO treatment induced strong Sub G(1) and G(0)/G(1) phase cell cycle arrest in a dose-dependent manner in PC-3. SIO exposure for 24 h decreased the expression of the anti-apoptotic protein Bcl-2 and increased the expression of the apoptogenic protein Bax. Moreover, the Bax/Bcl-2expression ratio was increased. Concurrently, the expression of caspase-3 was upregulated. These data support our hypothesis that SIO has anticarcinogenic properties.
引用
收藏
页码:2153 / 2165
页数:13
相关论文
共 26 条
[1]   Apototic signaling cascades [J].
Ashe, PC ;
Berry, MD .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (02) :199-214
[2]   International epidemiology of prostate cancer: Geographical distribution and secular trends [J].
Baade, Peter D. ;
Youlden, Danny R. ;
Krnjacki, Lauren J. .
MOLECULAR NUTRITION & FOOD RESEARCH, 2009, 53 (02) :171-184
[3]   PRIMARY GLIAL TUMOR PATIENTS TREATED BY COMBINING CISPLATIN AND ETOPOSIDE [J].
BOIARDI, A ;
SILVANI, A ;
MILANESI, I ;
BOTTURI, M ;
BROGGI, G .
JOURNAL OF NEURO-ONCOLOGY, 1991, 11 (02) :165-170
[4]  
Braun K, 2009, INT J MED SCI, V6, P338
[5]   Prostate cancer incidence and mortality trends in 37 European countries: An overview [J].
Bray, F. ;
Lortet-Tieulent, J. ;
Ferlay, J. ;
Forman, D. ;
Auvinen, A. .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (17) :3040-3052
[6]   The BCL2 family: Regulators of the cellular life-or-death switch [J].
Cory, S ;
Adams, JM .
NATURE REVIEWS CANCER, 2002, 2 (09) :647-656
[7]  
Den Brok MWJ, 2005, PDA J PHARM SCI TECH, V59, P246
[8]  
Ding Guo-Fang, 2011, Chinese Journal of Natural Medicines, V9, P151, DOI 10.3724/SP.J.1009.2011.00151
[9]   Targeting apoptosis pathways in cancer therapy [J].
Ghobrial, IM ;
Witzig, TE ;
Adjei, AA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (03) :178-194
[10]   A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies [J].
Goel, Sanjay ;
Mita, Alain C. ;
Mita, Monica ;
Rowinsky, Eric K. ;
Chu, Quincy S. ;
Wong, Nancy ;
Desjardins, Christopher ;
Fang, Fang ;
Jansen, Mendel ;
Shuster, Dale E. ;
Mani, Sridhar ;
Takimoto, Chris H. .
CLINICAL CANCER RESEARCH, 2009, 15 (12) :4207-4212